Our studies demonstrate that acute degradation of IRS2 recapitulates the reduction of tumor cell invasion that we previously observed upon chronic IRS2 loss, validating further investigation of how targeting IRS2 may impact tumor progression. The gene discussed is IRS2; the disease is neoplasm.